Mansoor Raza Mirza, MD, discusses treatment outcomes with the use of dostarlimab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer whose disease was mismatch repair deficient/microsatellite instability–high, TP53 mutated, or had no specific molecular profile.